Back

Large-Scale Chemical-Genetic Interaction Profiling Identifies a Novel Small-Molecule Inhibitor of Mycobacterium tuberculosis Polyketide Synthase 13

Gomez, J. E.; Solomon, M. Y.; Hunt, D. K.; Geddes, E. J.; Bond, A. N.; Liu, C.; Ulrich, R. J.; Chaudhary, P. V.; Hung, D. T.

2026-02-07 microbiology
10.64898/2026.02.06.704361 bioRxiv
Show abstract

PROSPECT (PRimary screening Of Strains to Prioritize Expanded Chemistry and Targets) is an antimicrobial discovery platform based on chemical-genetic interaction (CGI) profiling of compounds against a pool of Mycobacterium tuberculosis (Mtb) hypomorphs, each depleted of an essential gene. From prior screening data, we have now identified a novel N-oxolan-3-yl pyrazole carboxamide inhibitor (BRD1554) that had increased, selective activity against strains depleted of polyketide synthase 13 (Pks13), an essential enzyme in mycolic acid synthesis, and Rv2581c, an uncharacterized protein similar to glyoxylase II enzymes. Perturbagen CLass (PCL) analysis, a reference-based approach to mechanism of action (MOA) assignment from PROSPECT, predicted Pks13, a polyketide synthase with five catalytic domains responsible for the terminal condensation step in mycolic acid biosynthesis, was the likely target, potentially implicating the thioesterase domain. We synthesized a more active analogue while assigning the absolute stereochemistry of the active diastereomer, resulting in 1554-06-3R,4S with an MIC90 of 3.0 {micro}M against Mtb H37Rv. Exposure to 1554-06 led to the upregulation of the pks13 operon along with the iniBAC operon and other genes linked to mycolic acid synthesis. Isolation of mutants resistant to 1554-06 revealed single nucleotide polymorphisms in the thioesterase domain of Pks13. Finally, we biochemically confirmed that 1554-06 inhibits the activity of recombinant Pks13 thioesterase domain, with computational docking of 1554-06 steroisomers consistent with the stereospecific activity seen in whole cell assays. We found unique chemical genetic interactions between inhibitors of the different Pks13 domains and different detoxifying enzymes of Mtb, thus revealing novel gene-gene interactions. These results highlight how PROSPECT can not only immediately reveal, with domain-level resolution, the MOA of new whole-cell active chemical inhibitors of Mtb, allowing the integration of biological insight into compound triage and accelerated early development, but can also illuminate genetic interactions linked to those mechanisms that could inform predictions of synergy for antitubercular drug development. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=74 SRC="FIGDIR/small/704361v1_ufig1.gif" ALT="Figure 1"> View larger version (23K): org.highwire.dtl.DTLVardef@9a4f38org.highwire.dtl.DTLVardef@c70cd2org.highwire.dtl.DTLVardef@1ac2e1org.highwire.dtl.DTLVardef@f06df0_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Nature
575 papers in training set
Top 2%
14.7%
2
Cell Chemical Biology
81 papers in training set
Top 0.1%
12.7%
3
Nature Communications
4913 papers in training set
Top 18%
10.1%
4
Science
429 papers in training set
Top 3%
8.4%
5
Cell
370 papers in training set
Top 3%
6.4%
50% of probability mass above
6
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 16%
4.3%
7
Cell Host & Microbe
113 papers in training set
Top 1%
4.0%
8
eLife
5422 papers in training set
Top 25%
3.6%
9
Cell Systems
167 papers in training set
Top 4%
3.1%
10
Cell Reports
1338 papers in training set
Top 18%
2.9%
11
Nature Chemical Biology
104 papers in training set
Top 1%
2.6%
12
Cell Reports Medicine
140 papers in training set
Top 3%
1.9%
13
Chemical Science
71 papers in training set
Top 0.8%
1.9%
14
Nature Methods
336 papers in training set
Top 4%
1.8%
15
Journal of the American Chemical Society
199 papers in training set
Top 3%
1.7%
16
ACS Chemical Biology
150 papers in training set
Top 1%
1.7%
17
iScience
1063 papers in training set
Top 22%
1.2%
18
Communications Biology
886 papers in training set
Top 14%
1.2%
19
The Lancet Infectious Diseases
71 papers in training set
Top 2%
0.9%
20
Cell Genomics
162 papers in training set
Top 5%
0.9%
21
Nature Structural & Molecular Biology
218 papers in training set
Top 4%
0.8%
22
Nature Biotechnology
147 papers in training set
Top 7%
0.8%
23
Science Advances
1098 papers in training set
Top 28%
0.8%
24
mBio
750 papers in training set
Top 11%
0.8%
25
ACS Central Science
66 papers in training set
Top 2%
0.7%
26
Nucleic Acids Research
1128 papers in training set
Top 20%
0.6%